Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlodipine + olmesartan + ezetimibe + rosuvastatin
- Development stage
- Phase 3
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWJ1451 is a fixed-dose combination oral tablet containing four active pharmaceutical ingredients: amlodipine (a calcium channel blocker), olmesartan (an angiotensin II receptor antagonist), rosuvastatin (an HMG-CoA reductase inhibitor/statin), and ezetimibe (a cholesterol absorption inhibitor). It is being developed by Daewoong Pharmaceutical for the treatment of essential hypertension and primary hypercholesterolemia, as well as dyslipidemia. The drug leverages multiple mechanisms to address both elevated blood pressure and abnormal lipid profiles in patients at risk for cardiovascular disease. Clinical development has reached Phase III for dyslipidemias and hypertension[5][7].
- Brand names
- Nukreos
- Other names
- amlodipine/olmesartan/ezetimibe/rosuvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on amlodipine + olmesartan + ezetimibe + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlodipine + olmesartan + ezetimibe + rosuvastatin.